Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-01-31
2008-10-28
Rao, Manjunath (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C530S399000, C530S397000
Reexamination Certificate
active
07442684
ABSTRACT:
This invention provides VEGF-FSH compounds having increased serum half-lives relative to either native VEGF or FSH, in which both VEGF and FSH are biologically active. This invention also provides related compositions and methods for increasing fertility, egg production and spermatogenesis in a subject, as well as methods for increasing vascularization in a tissue, particularly in ovarian tissue.
REFERENCES:
patent: 4179337 (1979-12-01), Davis
patent: 5585345 (1996-12-01), Boime
patent: 5712122 (1998-01-01), Boime et al.
patent: 5759818 (1998-06-01), Boime
patent: 5958737 (1999-09-01), Boime et al.
patent: 5985611 (1999-11-01), Boime
patent: 6040157 (2000-03-01), Hu et al.
patent: 6225449 (2001-05-01), Boime
patent: 6242580 (2001-06-01), Boime et al.
patent: 6306654 (2001-10-01), Boime et al.
patent: 7173113 (2007-02-01), Lustbader et al.
patent: WO 03/064619 (2003-08-01), None
Gabrilovich et al. 2003. Chapter 44 in the Cytokine Handbook, 4thedition. Ed: Thomson et al. Academic Press, pp. 1017-1034.
Backer et al. 2001. Protein Expression and Purification 23:1-7.
Arora N. et al. 1999. Cancer Res. 59:183-188.
Halin C et al. 2002. Int J Cancer 102:109-116.
International Search Report issued Dec. 1, 2003 in connection with PCT International Application No. PCT/US03/02982: and.
Ben-Menahem et al. (2001) The Position of the Alpha and Beta Subunits in a Single Chain Variant of Human Chorionic Gonadotropin Affects the Heterodimeric Interaction of the Subunits and Receptor-Binding Epitope. J. Biol. Chem. 276:29871-879.
Bouloux, P. M. et al. (2001) First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males.Hum. Reprod. 16, 1592-1597.
Calvo, F. O. et al. (1986) Deglycosylated human follitropin: characterization and effects on adenosine cyclic 3′, 5′-phosphate production in porcine granulosa cells.Biochemistry 25, 3938-3943.
Chui, D. K. et al. (1997) Follicular vascularity—the predictive value of transvaginal power Doppler ultrasonography in an in vitro fertilization programme: a preliminary study.Hum. Reprod. 12, 191-196.
Dissen, G. A. et al. Ojeda (1994) Immature rat ovaries become revascularized rapidly after autotransplantation and show a gonadotropin-dependent increase in angiogenic factor gene expression.Endocrinology134, 1146-1154.
Fares, F. A. et al. (1992) Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit.Proc. Natl. Acad. Sci U.S.A. 89, 4304-4308.
Feng, W. et al. (1995) The asparagine-linked oligosaccharides of the human chorionic gonadotropin beta subunit facilitate correct disulfide bond pairing.J. Biol. Chem. 270, 11851-11859.
Ferrara, N. et al. (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis.Nat. Med. 4, 336-340.
Ferrara, N. et al. (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins.Endocr. Rev. 13, 18-32.
Krichevsky, A. et al. (1994) The development of a panel of monoclonal antibodies to human luteinizing hormone and its application to immunological mapping and two-site assays.Endocrine 2. 511-520.
LeContonnec, J.Y. et al. (1994) Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady-state pharmacokinetics.Fertil. Steril. 61, 679-86.
Lindau-Shapard, B.A. et al. (2001) Reversible immunoneutralization of human follitropin receptor.J. Reprod. Immun. 49, 1-19.
Matzuk, M. M. et al. (1990) The biological role of the carboxyl-terminal extension of human chorionic gonadotropin beta-subunit.Endocrinology 126, 376-383.
Nargund, G. et al. (1996) Associations between ultrasound indices of follicular blood flow, oocyte recovery and preimplantation embryo quality.Hum. Reprod. 11, 109-113.
Pedersen, T. and H. Peters (1968) Proposal for a classification of oocytes and follicles in the mouse ovary.J. Reprod. Fertil. 17, 555-557.
Pierce, J. G. and T. F. Parsons (1981) Glycoprotein hormones: structure and function.Annu. Rev. Biochem. 50, 465-495.
Porchet, H.C. et al. (1995) Pharmacokinetics of recombinant human luteinizing hormone.J. Clin. Endocrinol. Metab. 80, 667-73.
Saal, W. et al. (1991) Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin.Fertil. Steril. 56, 225-8.
Sairam, M. R. and P. Manjunath (1982) Studies on pituitary follitropin. XL Induction of hormonal antagonistic activity by chemical deglycosylation.Mol. Cell Endocrinol. 28, 139-150.
Sugahara, T. et al. (1996) Characterization of the O-glycosylation sites in the chorionic gonadotropin beta subunit in vivo using site-directed mutagenesis and gene transfer.J. Biol. Chem. 271, 20797-20804.
Suganuma, N. et al. (1989) Elimination of disulfide bonds affects assembly and secretion of the human chorionic gonadotropin beta subunit.J. Biol. Chem. 264, 19302-19307.
Van Blerkom, J. et al. (1997) The developmental potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: association with vascular endothelial growth factor levels and perifollicular blood flow characteristics.Hum. Reprod. 12, 1047-1055.
Yen, S. S. et al. (1968) Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man.J. Clin. Endocrinol. Metab. 28, 1763-1767.
U.S. Appl. No. 10/062,931, filed Jan. 31, 2002, Joyce Lustbader et al.
Amendment submitted Feb. 22, 2005 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Amendment submitted May 16, 2005 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Amendment submitted Oct. 19, 2005 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Amendment submitted Jun. 5, 2006 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Amendment submitted Aug. 18, 2006 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Interview Summary included with the Notice of Allowance issued Sep. 14, 2006 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Invitation to Pay Additional Fees issued Sep. 5, 2003 in connection with PCT International Application No. PCT/US03/02982, filed Jan. 31, 2003.
Notification of Transmittal of the International Search Report or the Declaration, including International Search Report issued Dec. 1, 2003 in connection with PCT International Application No. PCT/US03/02982, filed Jan. 31, 2003.
Office Action issued Jan. 19, 2005 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Office Action issued Jul. 19, 2005 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Office Action issued Feb. 3, 2006 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Response to Sep. 5, 2003 Invitation to Pay Additional Fees submitted Sep. 18, 2003 in connection with PCT International Application No. PCT/US03/02982, filed Jan. 31, 2003.
Substitute Notice of Allowability, including Detailed Action and Interview Summaries issued Oct. 2, 2006 in connection with U.S. Appl. No. 10/119,427, filed Apr. 9, 2002.
Lobel Leslie
Lustbader Joyce
Cooper & Dunham LLP
Rao Manjunath
Shafer Shulamith H
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Long-acting hormone and growth factor compositions and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Long-acting hormone and growth factor compositions and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long-acting hormone and growth factor compositions and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3994441